Myopia Progression

Johnson & Johnson Vision released a new guide for eye care professionals and patients with research-based recommendations for assessing, monitoring and treating myopia, especially in children.

Haag-Streit Diagnostics has introduced Lenstar Myopia to combat the increasing demand for myopia management.

Eyenovia reported successful clinical trial results for three different ocular pharmaceutical solutions delivered with its Optejet microdose dispenser for mydriasis, myopia and presbyopia.

Topcon Healthcare introduced into the U.S. market the Aladdin-M, which measures corneal curvature, pupil dynamics and axial length metrics and incorporates features for keratoconus screening and contact lens fitting.

During a CooperVision-sponsored webinar announcing the U.S. launch of MiSight contact lenses for myopia control in pediatric patients, Michele Andrews, OD, suggested three at-home tests parents can use to determine whether their child can see a 20/20-sized letter.

MiSight daily disposable soft contact lenses were effective at slowing myopia progression compared with standard daily disposable lenses, according to study results published in Journal Optometry and Vision Science.

While annual myopia progression in children was linked to subsequent progression the next year, the correlation as a single factor was not significant enough to fully predict subsequent or long-term myopia progression.

A greater need for treatment and awareness of visual impairment issues such as myopia among the population in East Asian countries exists, according to findings published in the British Journal of Ophthalmology.

As people of all ages spend more time indoors during the COVID-19 quarantine, many eye care providers are pointing out the risks for increased eye strain caused by digital device use.

Executives from SightGlass Vision, developers of novel spectacles designed to slow myopia progression in children, are hoping this treatment option can help address the increasing prevalence of this condition worldwide.